CELL INTELLIGENCE · 肿瘤细胞治疗研究

弥漫大 B 细胞淋巴瘤的免疫治疗：从单克隆抗体到细胞治疗（叙述性综述）

Immunotherapy of diffuse large B-cell lymphoma: from monoclonal antibodies to cellular therapies. A narrative review.

B 细胞淋巴瘤中的 CAR-NK 细胞：迈向可及且可扩展细胞治疗的新前沿

CAR-NK Cells in B-cell Lymphoma: A New Frontier toward Accessible and Scalable Cellular Therapy.

TAK-007 在复发/难治性 B 细胞非霍奇金淋巴瘤成人患者中的安全性和疗效：一项 2 期开放标签多中心研究

A Phase 2, Open-Label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma.

克服 CAR-T 与 CAR-NK 细胞疗法中的耐药与复发：从实验室到临床

Overcoming Resistance and Relapse in CAR-T and CAR-NK Cell Therapies: From Bench to Bedside.

靶向药物治疗与抗 CD19 CAR NK 细胞免疫治疗在急性淋巴细胞白血病中的联合应用

Combination of targeted pharmacotherapy and immunotherapy with anti-CD19 CAR NK cells in acute lymphoblastic leukemia.

超越 CAR-T：CAR-NK/T 细胞在血液肿瘤中的兴起

Beyond CAR-T: The Rise of CAR-NK/T Cells for Haematological Cancer.

CAR-NK/T 细胞可能被证明是治疗血液系统恶性肿瘤的一种更安全、更灵活的细胞疗法。

作者更正：4-1BB 共刺激 CD19 特异性 CAR-NK 细胞疗法治疗复发/难治性大 B 细胞淋巴瘤的安全性与可行性：I 期试验

Author Correction: Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory/relapsed large B cell lymphoma: a pha

4-1BB 共刺激 CD19 特异性 CAR-NK 细胞治疗难治/复发性大 B 细胞淋巴瘤的安全性与可行性：一项 1 期试验

Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory/relapsed large B cell lymphoma: a phase 1 trial.

白细胞介素-21 工程化经富集的代谢通路增强 CD19 特异性 CAR-NK 细胞抗 B 细胞淋巴瘤活性

Interleukin-21 engineering enhances CD19-specific CAR-NK cell activity against B-cell lymphoma via enriched metabolic pathways.

CD19-CAR-NK/T（CD19CAR-NK 细胞）治疗 B 细胞淋巴瘤、套细胞淋巴瘤：I 期临床试验

Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell Lymphoma

这是一项 I 期注册临床试验，评估 CD19CAR-NK 细胞治疗 B 细胞淋巴瘤、套细胞淋巴瘤、弥漫大 B 细胞淋巴瘤的疗效与安全性。当前状态：招募中。计划入组 52 例。试验地点：中国 · 杭州（共 1 个中心，其中中国 1 个）。登记号：NCT06464861。